

A pilot study of D-cycloserine-augmented cognitive behavioural therapy (CBT) with exposure therapy in adolescents with obsessive-compulsive disorder (OCD)

Submission date 22/12/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 05/02/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 25/11/2013	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Dr Isobel Heyman

Contact details

Department of Child and Adolescent Psychiatry - PO85

Institute of Psychiatry

De Crespigny Park

London

United Kingdom

SE5 8AF

+44 (0)20 3228 5222

i.heyman@iop.kcl.ac.uk

Additional identifiers

Protocol serial number

RAA2008-014

Study information

Scientific Title

A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder

Study objectives

The principal research objective is to establish the clinical effectiveness of D-cycloserine- (DCS-) augmented cognitive behavioural therapy (CBT) for children and adolescents with obsessive-compulsive disorder (OCD). Our hypothesis is that the effectiveness of CBT for OCD, and speed of recovery, can be improved by the addition of a small dose of DCS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Kings College Hospital Research Ethics Committee (REC) gave approval in December 2008 (ref: 08/H0808/203)

Study design

Single-centre double-blind randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Obsessive-compulsive disorder

Interventions

The trial will consist of two arms. In the first arm, young people will receive cognitive behaviour therapy with a small dose of D-cycloserine (50 mg) given after sessions 3 to 12. In the second arm, young people will receive cognitive behaviour therapy with a placebo pill given after sessions 3 to 12.

Total duration of treatment in both arms is 14 weeks, and total duration of follow-up in both arms is 12 months, with follow-up evaluations planned to occur at 3 months, 6 months, and 12 months.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

D-cycloserine

Primary outcome(s)

Children's Yale Brown Obsessive Compulsive Scale (CYBOCS), a well-validated clinician administered measure of OCD severity. For each arm, this measure will be administered at the beginning of each session, and again at 3 months, 6 months and 12 months post-treatment.

Key secondary outcome(s)

1. Diagnosis of OCD as determined with:
 - 1.1. The Anxiety Disorders Interview Schedule for DSM-IV (ADIS), the Child Obsessive-Compulsive Inventory (ChOCI), child and parent versions
 - 1.2. The Strengths and Difficulties Questionnaire (SDQ), child and parent versions
 - 1.3. The Beck Depression Inventory for Youth (BDI-Y)
 - 1.4. The Depression Anxiety and Stress Scale (DASS) for parents
 - 1.5. The Family Accommodation Scale (FAS)
2. Additional process variables include measures of trait anxiety (RCMAS), threat perception (CARBQ-C/P), subjective anxiety (SUDS ratings), behavioural avoidance tasks (BATs), physiological arousal (heart rate variability) and the Patient Exposure Adherence Scale (PEAS)
3. Behavioural Avoidance Task (BAT). A single task, single-step BAT will be administered. The task will be described to the child using standardised instructions. The BAT is an individually tailored task in which the young person is asked to expose him/herself to a situation that usually causes him/her significant distress or results in compulsive rituals.
4. Subjective units of distress (SUDS). Young people will be asked to rate their subjective distress at various time points during the BAT task, based on an 8-point Likert scale thermometer (0 = none to 8 = extreme).
5. Heart Rate Variability (HRV). HRV is a measure of the beat-to-beat variations in heart rate. It is calculated by analysing a time series of beat-to-beat intervals from a heart rate monitor. HRV is an indicator of autonomic arousal, and there is a known relationship between HRV and emotional arousal. HRV has been shown to be sensitive to the emotion of fear in most people. Therefore HRV will be used as a measure of physiological arousal in relation to the BAT task. HRV will be measured using a Polar heart rate monitor (FT80). A heart rate monitor consists of two elements: a chest strap transmitter and a wrist receiver (a sports watch). The chest strap has electrodes in contact with the skin to monitor electrical voltages in the heart.
6. Cognitive and Avoidant Response Bias Questionnaire - Child and Parent Versions (CARBQ-C/P). Threat perception and coping expectations in response to both generic, non-salient situations as well as to personally salient situations (i.e. situations that the young person perceives to be anxiety provoking) will be measured using the Cognitive and Avoidant Response Bias Questionnaire (CARBQ). It is also of interest to examine parents (mothers) levels of threat perception and coping expectations for their child.

Secondary outcome measures will be completed at 3 months, 6 months and 12 months post-treatment.

Completion date

28/02/2010

Eligibility

Key inclusion criteria

1. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of OCD
2. Aged 12 to 18 years
3. Either sex

4. Any ethnicity, religious background or sexual orientation
5. Referred to the National and Specialist OCD Clinic at Maudsley Hospital
6. If on medication, this should be stable for 12 weeks and not be changed during the course of the trial
7. Provision of written informed consent (patient and carer)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

12 years

Upper age limit

18 years

Sex

All

Key exclusion criteria

1. Current diagnosis of psychosis, current alcohol or substance abuse/dependence
2. English too poor to engage in treatment
3. Severe disabling neurological disorder
4. Medical contraindication to cycloserine, including epilepsy and porphyria
5. A diagnosed global learning disability or pervasive developmental disorder
6. Characteristics interfering with completion of treatment, e.g. life threatening or unstable medical illness
7. Pregnancy
8. Not suitable for CBT (selective mutism, lack of insight or motivation for change)

Date of first enrolment

01/02/2009

Date of final enrolment

28/02/2010

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Department of Child and Adolescent Psychiatry - PO85

London
United Kingdom
SE5 8AF

Sponsor information

Organisation

Institute of Psychiatry, Kings College London (UK)

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK) - Biomedical Research Centre for Mental Health (ref: PAXKAYI)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2014		Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes